Breathe Well Live Well
|
Boston Scientific Shows Upbeat Data
Daily Markets Leading medical devices player Boston Scientific (NYSE:BSX) presented positive data from the Research in Severe Asthma (RISA) trial at a conference in Amsterdam. It was observed that patients with severe refractory asthma, when treated with Alair … Boston Scientific begins enrolment for nerve stimulation trial |
View full post on asthma – Google News
|
Research and Markets: Asthma Therapeutics – Pipeline Assessment and Market …
SunHerald.com GlobalData, the industry analysis specialist, has released its new report, Asthma Therapeutics – Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Asthma Therapeutics market. … |
View full post on asthma – Google News
|
Research and Markets: the Asthma, COPD & Allergic Rhinitis Market Outlook to …
Business Wire (press release) The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical … |
View full post on asthma – Google News
|
Boston Scientific Targets Asthma
Daily Markets Leading medical devices player Boston Scientific Corporation (NYSE:BSX) presented long-term safety data from the Research in Severe Asthma (RISA) trial. The study revealed that patients with severe refractory asthma, when treated with Alair bronchial … |
View full post on asthma – Google News
 Stockopedia |
Verona Pharma Receives Positive Results For Asthma Treatment At Higher Doses
Daily Markets By Stockopedia on February 22, 2011 | More Posts By Stockopedia | Author's Website Verona Pharma (LON:VRP) , the AIM listed biotech company with a focus on developing treatments for chronic respiratory diseases such as asthma, has completed a … Verona Pharma announces positive results from mild asthma study |
View full post on asthma – Google News
|
Verona Pharma announces positive results from mild asthma study
Trading Markets (press release) Verona Pharma plc, a biotechnology company, has completed a successful trial of higher doses of its lead respiratory drug, RPL554, in patients with mild asthma. The randomized, blinded trial, with placebo control, took place in Leiden, The Netherlands, … |
View full post on asthma – Google News
|
Targacept Begins Phase 2 Studies of TC-6987 in Asthma and Type 2 Diabetes
Trading Markets (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … |
View full post on asthma – Google News
|
Kohl's Helps Kids Breath a Little Easier
Trading Markets (press release) On January 12, Kohl's associates will volunteer at Children's National Medical Center's "Waiting to Exhale" asthma education session and present a check for … |
View full post on asthma – Google News
|
Research and Markets: The Asthma, COPD & Allergic Rhinitis Market Outlook to 2015
Business Wire (press release) Global sales of asthma, COPD and allergic rhinitis drugs are expected to decline from $46bn in 2009 to $43bn in 2015, due to patent expiries on leading … |
View full post on asthma – Google News
 Proactive Investors UK |
VERONA PHARMA PLC – New Higher Dose RPL554 Clinical Trial in Asthma
Trading Markets (press release) This study is the first of two further trials with RPL554 in patients with allergic asthma. Based on the results, it will determine the dosage used in a … Verona Pharma starts Asthma drug trial STOCKS NEWS UK-Verona gains positive update on key drug Verona Pharma up 20% on new drug trial |
View full post on asthma – Google News